Mounjaro risks and side effects: what to weigh before you start

The side effects most people actually encounter

Nausea is the one patients mention most. It tends to peak in the day or two after an injection and then fade, particularly once the body has had a few weeks at a given dose. Loose stools, constipation, indigestion, bloating and burping sit in the same category, common, manageable, and for most people not a reason to stop. Fatigue and headache are reported too, usually early in treatment.

The NHS tirzepatide medicines page lists these in full and is worth bookmarking. The pattern behind them is straightforward: Mounjaro slows how quickly food moves through the stomach, and the gut takes time to adapt. Starting at the lowest dose (2.5mg) exists precisely to let that adjustment happen gradually, not to produce weight loss immediately.

Injection-site reactions (redness, mild swelling, brief discomfort) are also possible. Rotating between the abdomen, thigh and upper arm helps. If you find injections more anxiety-inducing than you expected, that is an entirely understandable feeling and something our prescribers hear about regularly. The technique becomes routine quickly for most people, and the detailed side effects guide covers it further.

Risks that are less common but clinically important

Pancreatitis (inflammation of the pancreas) is the risk that carries the most weight in clinical conversations. It is infrequent, but it can be serious. In January 2026 the MHRA issued a Drug Safety Update specifically for GLP-1 medicines, reinforcing that severe stomach pain, particularly pain that radiates toward the back, with or without vomiting, should prompt immediate medical attention. Do not wait to see if it passes.

Gallbladder problems are also documented with GLP-1 medicines: gallstones and gallbladder inflammation. Symptoms include upper-right abdominal pain, nausea and fever. Dehydration from prolonged vomiting or diarrhoea can strain the kidneys, which is another reason to manage GI effects rather than push through them silently.

There has been research interest in a possible thyroid signal. Animal studies raised questions, but the human evidence is not conclusive. The full picture on longer-term risks continues to be monitored, Mounjaro carries a Black Triangle (▼) from the MHRA, meaning it is subject to additional surveillance. For a clear account of where the evidence currently sits on specific concerns, including a thorough look at tirzepatide risks and side effects, the overview of Mounjaro's risk evidence goes deeper, and the cancer risk section addresses thyroid and other questions directly.

If you notice sudden changes to your eyesight, seek advice promptly. This is most relevant in people with diabetes, and the eyesight side effects page explains what is known.

When to get medical help, and when to call 999

Some symptoms should not be managed at home or with a pharmacist. Contact a doctor or call 111 if you develop: severe or persistent stomach pain (especially spreading to the back), signs of a serious allergic reaction (swelling of the face, throat or tongue, difficulty breathing, a rash spreading rapidly), persistent vomiting that prevents you keeping fluids down, or symptoms that suggest gallbladder trouble.

Call 999 or go to A&E if you have a severe allergic reaction, chest tightness, or any symptom that feels acutely dangerous.

For symptoms that are uncomfortable but not urgent (persistent nausea after several weeks, feeling sick consistently, or injection-site changes) contact whoever prescribed your treatment. At nume, our aftercare team is available seven days a week specifically for this.

You can report any side effect you suspect is linked to Mounjaro, including one not listed in the leaflet, directly to the MHRA Yellow Card scheme. Patient reports genuinely contribute to post-market safety monitoring.

Who should not take Mounjaro, and what the prescriber considers

Tirzepatide is not suitable for everyone. A personal or family history of medullary thyroid carcinoma or a condition called MEN2 (multiple endocrine neoplasia type 2) is a contraindication. A history of pancreatitis warrants careful discussion. Severe gastrointestinal conditions, certain kidney impairments, and some other medicines may all affect suitability.

Tirzepatide is not recommended during pregnancy or breastfeeding, and the MHRA advises using reliable contraception during treatment. Women taking the oral contraceptive pill should use an additional barrier method for the first four weeks of treatment and for four weeks after any dose increase, because the pill's absorption may be reduced. The NHS England weight-management injections guidance covers this, and transdermal HRT (patches or gels) is preferred over oral HRT for the same reason. Under-18s are not licensed to use Mounjaro.

BMI alone does not decide suitability. The prescribers at nume look at your full medical picture. If you are considering treatment, the right starting point is a consultation where these risks can be assessed for your specific circumstances, our prescribers discuss suitability and side effects as part of every assessment. Start your free consultation to begin that conversation.